Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kairos Pharma (KAPA) Return on Sales (2024 - 2025)

Kairos Pharma (KAPA) has disclosed Return on Sales for 2 consecutive years, with 0.03% as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Return on Sales fell 1953.0% year-over-year to 0.03%, compared with a TTM value of 0.05% through Jun 2025, changed N/A, and an annual FY2024 reading of 0.06%, down 4187.0% over the prior year.
  • Return on Sales was 0.03% for Q2 2025 at Kairos Pharma, down from 0.03% in the prior quarter.
  • Across five years, Return on Sales topped out at 19.5% in Q2 2024 and bottomed at 0.03% in Q2 2025.